MAP2K7 and cancer: On the contrary, we observed that these gene signatures induced increased sensitivity of cancer cell lines to several MEK inhibitors, including trametinib, selumetinib, 17-AAG, RDEA119, PD-0325901, (5Z)-7-oxozeaenol, and, a mutant-BRAF kinase inhibitor, dabrafenib (Figure 7), suggesting that this class of anti-cancer drugs may still be useful in the treatment of thyroid cancer.